SVA.V

Sernova Corp. (SVA.V) Achieves Insulin Independence in Phase 1/2 Clinical Trial

Sernova Corp. $435.182M Market Capitaliztion Sernova Corp. (SVA.V) has provided a progress update on the Company’s Phase 1/2 type 1 diabetes (T1D) clinical trial in… Read More »Sernova Corp. (SVA.V) Achieves Insulin Independence in Phase 1/2 Clinical Trial

A Harvard University Study calculates the economic burden from diabetes at about $1.3 trillion, or 1.8% of global GDP.